Display options
Cite
Addington J, Liu L, Brummitt K, et al. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophr Res. 2020;doi: 10.1016/j.schres.2020.04.010.
Addington, J., Liu, L., Brummitt, K., Bearden, C. E., Cadenhead, K. S., Cornblatt, B. A., Keshavan, M., Mathalon, D. H., McGlashan, T. H., Perkins, D. O., Seidman, L. J., Stone, W., Tsuang, M. T., Walker, E. F., Woods, S. W., & Cannon, T. D. (2020). North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophrenia research, . https://doi.org/10.1016/j.schres.2020.04.010
Addington, Jean, et al. "North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description." Schizophrenia research vol. (2020). doi: https://doi.org/10.1016/j.schres.2020.04.010
Addington J, Liu L, Brummitt K, Bearden CE, Cadenhead KS, Cornblatt BA, Keshavan M, Mathalon DH, McGlashan TH, Perkins DO, Seidman LJ, Stone W, Tsuang MT, Walker EF, Woods SW, Cannon TD. North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description. Schizophr Res. 2020 Apr 18; doi: 10.1016/j.schres.2020.04.010. Epub 2020 Apr 18. PMID: 32317224; PMCID: PMC7572535.
Copy Download .nbib Format: NLM
Share it on

Schizophr Res. 2020 Apr 18; doi: 10.1016/j.schres.2020.04.010. Epub 2020 Apr 18.

North American Prodrome Longitudinal Study (NAPLS 3): Methods and baseline description.

Schizophrenia research

Jean Addington, Lu Liu, Kali Brummitt, Carrie E Bearden, Kristin S Cadenhead, Barbara A Cornblatt, Matcheri Keshavan, Daniel H Mathalon, Thomas H McGlashan, Diana O Perkins, Larry J Seidman, William Stone, Ming T Tsuang, Elaine F Walker, Scott W Woods, Tyrone D Cannon

Affiliations

  1. Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address: [email protected].
  2. Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.
  3. Department of Psychiatry and Biobehavioral Sciences, UCLA, Los Angeles, CA, United States of America.
  4. Department of Psychiatry, UCSD, San Diego, CA, United States of America.
  5. Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States of America.
  6. Department of Psychiatry, Harvard Medical School at Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, MA, United States of America.
  7. Department of Psychiatry, UCSF, and SFVA Medical Center, San Francisco, CA, United States of America.
  8. Department of Psychiatry, Yale University, New Haven, CT, United States of America.
  9. Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States of America.
  10. Department of Psychiatry, UCSD, San Diego, CA, United States of America; Institute of Genomic Medicine, University of California, La Jolla, CA, United States of America.
  11. Departments of Psychology and Psychiatry, Emory University, Atlanta, GA, United States of America.
  12. Department of Psychology, Yale University, New Haven, CT, United States of America.

PMID: 32317224 PMCID: PMC7572535 DOI: 10.1016/j.schres.2020.04.010

Abstract

The North American Prodrome Longitudinal Study (NAPLS) is a consortium of nine programs focusing on youth at clinical high risk (CHR) for psychosis. Funded by the National Institute of Mental Health (NIMH), the sites are located at Emory University, Harvard University, University of Calgary, University of California at Los Angeles, at San Diego, and at San Francisco, University of North Carolina Chapel Hill, Yale University, and Zucker Hillside Hospital. There have been two previous endeavors completed by this consortium, known as NAPLS-1 and NAPLS-2. This paper first offers an overview of the methodology of the third phase of the NAPLS consortium, the second five-year prospective study NAPLS-3, which aims to determine mechanisms of the development of psychosis. In addition, we report on the ascertainment and demographics of the 710 CHR participants in NAPLS-3.

Copyright © 2020 Elsevier B.V. All rights reserved.

Keywords: Clinical high risk; Methodology; Psychosis; Schizophrenia

Conflict of interest statement

Declaration of competing interest Authors declare they have no conflict of interest with respect to this study.

References

  1. BMJ. 2002 Nov 23;325(7374):1212-3 - PubMed
  2. Neuropsychopharmacology. 2017 Oct;42(11):2188-2195 - PubMed
  3. Biol Psychiatry. 2012 Mar 15;71(6):496-502 - PubMed
  4. Glia. 2013 Jan;61(1):24-36 - PubMed
  5. Brain Cogn. 2007 Dec;65(3):244-51 - PubMed
  6. Biol Psychiatry. 2006 May 15;59(10):929-39 - PubMed
  7. J Neuroimmunol. 2014 Apr 15;269(1-2):20-27 - PubMed
  8. Cereb Cortex. 2013 Oct;23(10):2394-406 - PubMed
  9. Biol Psychiatry. 2012 Mar 15;71(6):512-20 - PubMed
  10. Semin Immunopathol. 2013 Sep;35(5):601-12 - PubMed
  11. Biol Psychiatry. 2015 Jan 15;77(2):147-57 - PubMed
  12. Nat Neurosci. 2014 Mar;17(3):400-6 - PubMed
  13. Neuron. 2014 Apr 2;82(1):195-207 - PubMed
  14. J Neurosci. 2005 Nov 9;25(45):10494-501 - PubMed
  15. Schizophr Bull. 2007 May;33(3):688-702 - PubMed
  16. Int J Psychophysiol. 2015 Feb;95(2):145-55 - PubMed
  17. J Neuroinflammation. 2014 Mar 04;11:40 - PubMed
  18. Psychiatry Res. 1989 May;28(2):193-213 - PubMed
  19. J Behav Med. 1987 Feb;10(1):61-74 - PubMed
  20. J Health Soc Behav. 1978 Jun;19(2):205-29 - PubMed
  21. Clin Neurophysiol. 2009 Mar;120(3):453-63 - PubMed
  22. Schizophr Bull. 2009 May;35(3):509-27 - PubMed
  23. Biol Psychiatry. 2008 Nov 1;64(9):820-2 - PubMed
  24. Schizophr Bull. 2007 May;33(3):665-72 - PubMed
  25. Psychiatry Res. 1989 Jul;29(1):65-85 - PubMed
  26. Am J Psychiatry. 2008 Feb;165(2):203-13 - PubMed
  27. Schizophr Bull. 1982;8(3):470-84 - PubMed
  28. Int J Psychophysiol. 2006 Jan;59(1):49-58 - PubMed
  29. Clinics (Sao Paulo). 2011;66 Suppl 1:3-17 - PubMed
  30. Schizophr Bull. 2016 Sep;42(5):1234-42 - PubMed
  31. Br J Psychiatry Suppl. 1993 Dec;(22):39-44 - PubMed
  32. Brain Behav Immun. 2012 Feb;26(2):337-45 - PubMed
  33. Am J Psychiatry. 2016 Oct 1;173(10):980-988 - PubMed
  34. Wiley Interdiscip Rev Cogn Sci. 2010 Sep;1(5):766-773 - PubMed
  35. Clin Dev Immunol. 2013;2013:608654 - PubMed
  36. Neuroimage. 2012 Oct 15;63(1):232-9 - PubMed
  37. Schizophr Res. 2012 Dec;142(1-3):77-82 - PubMed
  38. Neuron. 2012 May 24;74(4):691-705 - PubMed

Publication Types

Grant support